Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TaiGen Reports Positive Taiwan-China Data for Novel Antibiotic

publication date: Dec 3, 2015
TaiGen Biotech of Taiwan reported that the IV formulation of Taigexyn®, the company's novel antibiotic for drug-resistant infections, posted positive results in a Taiwan-China Phase III clinical trial in patients with community-acquired pneumonia. Taigexyn's oral formulation is approved in Taiwan, but the antibiotic is not yet available in China in any form. In 2012, Zhejiang Medicine paid $8 million for China rights to the Class 1.1 new drug, a novel non-fluorinated quinolone. TaiGen expects to file for China approval of the IV antibiotic in 2016. More details....

Stock Symbol: (TWO: 4157)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital